Document:

Document

Exhibit 10.2

First Amendment 
to the
Omnibus Benefit Restoration Plan of Sonoco Products Company
(Restated effective January 1, 2015)

Whereas, Sonoco Products Company (the “Company”) currently sponsors the Omnibus Benefit Restoration Plan of Sonoco Products Company, as restated effective January 1, 2015 (the “Plan”); 

Whereas, the Company’s Board of Directors (the “Board”) desires to streamline administration and operation of its 401(k) plan and to make employee benefits provided by the Company more competitive in the market by eliminating the current retirement contribution feature of the 401(k) plan, increasing matching contributions in the 401(k), and adding a new contribution to this Plan;

Whereas, the Board held a meeting on October 19, 2021, and approved amending the Plan as set forth herein;

Now, therefore, be it resolved that effective as of December 31, 2021, the Plan shall be amended as follows:

1.         The following language shall be added to the end of section 5.2(b):

            “No credits will be made with respect to this section 5.2(b) after the 2021 Plan Year credit is made.”

2.         New Section 5.7 shall be added to the Plan to read as follows:

“5.7       New Contribution. A new contribution shall be made to the Plan as follows:

(a)    Effective Date: This section is effective for Eligible Compensation earned after December 31, 2021;

(b)       Eligibility: Any nonunion Employee whose Eligible Compensation during a Plan Year exceeds the Social Security Wage Base in effect for such Plan Year;

(c )      Vesting: All contributions made pursuant to this section shall be 100% vested and nonforfeitable;

(d)       Contribution Amount: 4% of the amount that the nonunion Employee’s Eligible Compensation exceeds the Social Security Wage Base in effect for such Plan Year.

Resolved further, that the Benefits Committee will perform all acts necessary to effect the purposes of these amendments to the Plan, including (1) communicating the intent of the amendments to affected employees (as needed); and (2) establishing administrative procedures to properly operate the Plan, as amended.

* * * * *

1

In witness whereof, the undersigned, authorized to act on behalf of the Benefits Committee, hereby executes the foregoing resolutions which have been approved and authorized by the Benefits Committee, on this 19th day of October, 2021.

The Benefits Committee of
                                                                                    Sonoco Products Company

/s/John Florence                                                                                                                    
By: John Florence
Title: Vice President, General Counsel, Human Resources, and Secretary
2Document

Exhibit 10.1

									
	
	1100 Massachusetts Ave
Cambridge, MA
Tel: 617-453-1000
Fax: 617-453-1001
www.infi.com

                            

July 12, 2021

Stephane Peluso, Ph.D.
38 Algonquian Drive
Natick, MA 01760

Dear Stephane,

On behalf of Infinity Pharmaceuticals, Inc. (the “Company”), I am pleased to offer you the position of Senior Vice President, Chief Scientific Officer reporting to Adelene Perkins, Chief Executive Officer.

Effective Date: The effective date of your full-time employment with the Company shall be August 2, 2021, unless otherwise agreed upon. 

1.Salary:  Your base salary will be $15,384.62 per biweekly pay period (equivalent to $400,000 (USD) on an annualized basis). In addition, in accordance with the Company’s regular compensation practices, you may receive, approximately annually, a salary review, and the Company may adjust your salary based on your performance, the Company’s performance, and/or such other factors as may be determined at the sole discretion of the Company’s Board of Directors or its designee.

2.Contingent Compensation:  In addition to your salary and benefits, you are eligible to participate in the Company’s contingent compensation program beginning in the 2021 performance year. This program may result in a cash bonus as a percent of your base salary, with the target bonus for the 2021 performance year set at 40%. Your actual cash bonus may be higher or lower than the target bonus depending on your and the Company’s achievements of goals and objectives, as well as overall business conditions. The Contingent Compensation program is administered by the Company's Board of Directors in their sole discretion. In order to be eligible for any type of payment under the program, you must be actively employed by the Company at the time the payment is made. For clarity, any bonus paid under the Company’s contingent cash compensation program will not be prorated based on your hire date.

 

3.Equity Participation, Vesting of Stock Options:  Subject to the approval of the Compensation Committee of the Company’s Board of Directors, and as a material inducement to you entering into employment with the Company, upon the commencement of your employment with the Company, you will receive a one-time non-statutory stock option award to purchase 250,000 shares of the Company’s common stock as an “inducement grant” within the meaning of Nasdaq Listing Rule 5635(c)(4) outside the Company’s 2019 Stock Incentive Plan at an exercise price equal to the last reported sale price per share of the Company’s common stock on the Nasdaq stock exchange on the date of grant approval by the Compensation Committee of the Company’s Board of Directors (the “Option”).  The Option shall vest as to 12/48 of the shares on the first anniversary of your date of hire and as to 1/48 of the shares at the end of each calendar month thereafter.  The Option shall be evidenced by an option agreement that is consistent with the form of option agreement generally used by the Company and the terms of this letter and will be subject to all of the terms set forth in such written agreement covering the Option. 

4.Sign-On:  Subject to the approval of the Compensation Committee of the Company’s Board of Directors, and as a material inducement to you entering into employment with the Company, upon the commencement of your employment with the Company, you will receive a one-time restricted stock unit award (“RSU Award”) with respect to 50,000 shares of the Company’s common stock as an “inducement grant” within the meaning of Nasdaq Listing Rule 5635(c)(4) outside the Company’s 2019 Stock Incentive Plan. The RSU Award shall vest in full on the first anniversary of your date of hire. The RSU Award shall be evidenced by an agreement that is consistent with the form of agreement generally used by the Company and the terms of this letter and will be subject to all of the terms set forth in such written agreement. 

5.Benefits:  You may participate in any and all of the benefit programs that the Company establishes and makes available to its employees from time to time, provided you are eligible under (and subject to all provisions of) the plan documents governing these programs.  For clarity, you shall be eligible as a participant under the Company’s Executive Severance Benefits Plan, as amended and you shall be eligible for coverage under the Company’s Directors & Officers insurance policy in accordance with the terms and conditions of that policy.

6.Vacation and Holiday:  Upon your date of hire, you will start to accrue vacation time at a rate of 15 days per year, which may be taken in accordance with Company policy, provided however, the Company reserves the right to change its vacation policy at any time; paid holidays will be observed in accordance with the Company’s policy updated approximately annually. 

7.Employment At-Will:  Your employment with the Company will be at-will, meaning that you will not be obligated to remain employed by the Company for any specified period of time and the Company will not be obligated to continue your employment for any specific period.  Both you and the Company may terminate the employment relationship, with or without cause, at any time, with or without notice.  Similarly, nothing in this letter shall be construed as an agreement, either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company (except as explicitly described herein).

8.Proprietary Information, No Conflicts:  As a condition of employment, you agree to execute the Company’s standard form of Invention, Non-Disclosure, and Non-Competition Agreement and to be bound by all of the provisions thereof.  You hereby represent that you are not presently bound by any employment agreement, confidential or proprietary information agreement, or similar agreement with any current or previous employer that would impose any restriction on your acceptance of this offer or that would interfere with your ability to fulfill the responsibilities of your position with the Company.

9.Employment Eligibility Verification:  Please note that all persons employed in the United States are required to complete an Employment Eligibility Verification Form on the first day of employment and to submit an original document or documents that establish identity and employment eligibility within three business days of employment. 

10.Successors and Assigns:  This letter of offer will be binding upon and inure to the benefit of the Company’s successors and assignees.  In the event of a merger or consolidation (whether or not the Company is the surviving or the resulting corporation), the surviving or resulting corporation will be bound by the obligations set forth in this letter offer.

11.Contingencies:  This offer is expressly contingent upon the successful completion of a pre-employment background and reference check.  

Stephane, all of us at Infinity are very enthusiastic about your commitment to joining the Company and have the highest expectation of your future contributions.

Please indicate your understanding and acceptance of the foregoing terms of your employment by signing the enclosed copy of this letter and returning it to Seth Tasker no later than July 14, 2021.  After that date, the offer will expire.

Very truly yours,

			
	/s/ Adelene Q. Perkins

Adelene Q. Perkins
Chief Executive Officer

The foregoing correctly sets forth the terms of my at-will employment by Infinity Pharmaceuticals, Inc.

									
	/s/ Stephane Peluso, Ph.D.
		2021/07/12

	Stephane Peluso, Ph.D.
		Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00335-of-00352.parquet"}]]